Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fumoleau

Showing results (41-50 of 110) with videos related to

Pageof 11
Sort By:
Journal of Clinical Pharmacology|September 22, 2006
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancerSteven Zhang, Peter Zannikos, Ahmad Awada, et al.
Bulletin Du Cancer|October 1, 2015
[Clinical value of CA 15-3 for early detection of relapse in locally advanced breast cancer]Stéphane Konan, Vincent Goussot, Isabelle Desmoulins, et al.
BMC Cancer|April 17, 2015
Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapyEsther Schmitt, Frédérique Végran, Sandy Chevrier, et al.
BMC Cancer|April 4, 2013
Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumorsNicolas Isambert, Pierre Fumoleau, Catherine Paul, et al.
Gynecologic Oncology|January 30, 2010
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)Patricia Pautier, Florence Joly, Pierre Kerbrat, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 21, 2007
[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapyAlina Berriolo-Riedinger, Claude Touzery, Jean-Marc Riedinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trialJacques Bonneterre, Henri Roché, Pierre Kerbrat, et al.
Bulletin Du Cancer|November 1, 2006
[Appropriate cytotoxic drug usages in solid tumors: conformity to official labelling and level of scientific evidence]Ludwig Grangeasse, Bruno Coudert, Xavier Pivot, et al.
Breast Cancer Research and Treatment|September 16, 2011
Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancerAlexandre Cochet, Gaetan Quilichini, Inna Dygai-Cochet, et al.
Breast (Edinburgh, Scotland)|July 29, 2014
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study)Pierre Fumoleau, Kevin M Koch, Etienne Brain, et al.
Pageof 11

Showing results (41-50 of 110) with videos related to

Sort By:
Pageof 11
Journal of Clinical Pharmacology|September 22, 2006
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancerSteven Zhang, Peter Zannikos, Ahmad Awada, et al.
Bulletin Du Cancer|October 1, 2015
[Clinical value of CA 15-3 for early detection of relapse in locally advanced breast cancer]Stéphane Konan, Vincent Goussot, Isabelle Desmoulins, et al.
BMC Cancer|April 17, 2015
Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapyEsther Schmitt, Frédérique Végran, Sandy Chevrier, et al.
BMC Cancer|April 4, 2013
Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumorsNicolas Isambert, Pierre Fumoleau, Catherine Paul, et al.
Gynecologic Oncology|January 30, 2010
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)Patricia Pautier, Florence Joly, Pierre Kerbrat, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 21, 2007
[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapyAlina Berriolo-Riedinger, Claude Touzery, Jean-Marc Riedinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trialJacques Bonneterre, Henri Roché, Pierre Kerbrat, et al.
Bulletin Du Cancer|November 1, 2006
[Appropriate cytotoxic drug usages in solid tumors: conformity to official labelling and level of scientific evidence]Ludwig Grangeasse, Bruno Coudert, Xavier Pivot, et al.
Breast Cancer Research and Treatment|September 16, 2011
Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancerAlexandre Cochet, Gaetan Quilichini, Inna Dygai-Cochet, et al.
Breast (Edinburgh, Scotland)|July 29, 2014
A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study)Pierre Fumoleau, Kevin M Koch, Etienne Brain, et al.
Pageof 11